Pfizer-BioNTech COVID-19 Vaccine from Pfizer Inc. - A classic mRNA shot shaping long-term immunity
05.07.2026 - 02:27:10 | ad-hoc-news.de
By Nora Whitfield, ad hoc news Classics & Longsellers Desk. Reviewed July 05, 2026, 12:20 AM ET. Details in the imprint.
Pfizer-BioNTech COVID-19 Vaccine is the clear plastic vial nurses still line up in metal trays at CVS and Walgreens, the label slightly smudged from cold storage. You notice the sharp alcohol smell as pharmacist Michael Harris taps the syringe, then asks you to relax your shoulder for the familiar mRNA shot.
What the Pfizer-BioNTech shot is today
The Pfizer-BioNTech COVID-19 Vaccine, marketed as Comirnaty, is an mRNA-based vaccine designed to prevent COVID-19 caused by SARS-CoV-2 in adults and children as young as six months in the United States.FDA overview The formulation has evolved into strain-adapted versions, most recently aligned to the Omicron lineage to better match circulating variants.Pfizer product page
The vaccine uses lipid nanoparticles to deliver a small piece of genetic code that instructs human cells to make the spike protein, priming the immune system to recognize and fight the virus if exposed later.CDC mRNA explanation It does not contain live virus and cannot cause COVID-19 infection, a point Pfizer scientist Özlem Türeci has repeated in countless briefings.
More on Pfizer Inc. and its COVID-19 portfolio
For US retail investors tracking Pfizer Inc., Comirnaty remains a key reference point in vaccine revenues and long-term mRNA strategy.
US availability, schedules, and price signals
In the US, the Pfizer-BioNTech COVID-19 Vaccine is widely available in retail pharmacies, community clinics, and doctors' offices, with updated boosters recommended for most adults at least once per year based on CDC guidance.CDC schedule The product remains part of routine care for higher-risk groups such as seniors and immunocompromised patients.
List pricing sits around the mid- to high-80-dollar range per dose for the commercial market, while negotiated rates with public programs and insurers reduce the effective price that most US residents see.KFF pricing analysis At the counter, many insured patients pay no out-of-pocket cost, which has helped sustain booster uptake.
How Comirnaty fits in Pfizer's classic line-up
The Pfizer-BioNTech shot has shifted from emergency-only use to a long-term portfolio product, standing alongside established vaccines such as Prevnar and the meningococcal line in Pfizer's vaccines business.Pfizer vaccines overview CEO Albert Bourla now describes Comirnaty as part of a durable, seasonal franchise rather than a one-off pandemic surge.
Regulators have granted full approval for adult use and emergency authorization for pediatric use, reflecting extensive safety and efficacy data collected across billions of doses worldwide.FDA approval release The vaccine consistently shows strong protection against severe disease and hospitalization, even as variant-specific effectiveness against infection fluctuates.
Company context and stock link
For Pfizer Inc., the Pfizer-BioNTech COVID-19 Vaccine remains both a commercial pillar and a technology showcase for mRNA, supporting future programs in flu, RSV, and potentially oncology. Pfizer stock (NYSE: PFE) is closely watched by US retail investors as the company reallocates cash flows from Comirnaty toward new pipelines.
Key facts about the Pfizer-BioNTech COVID-19 Vaccine
- Product: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
- Manufacturer: Pfizer Inc.
- Category: Classics & Longsellers (vaccines)
- Launch: Initial EUA in December 2020, full US approval for adults in August 2021
- MSRP / Price: Approximately 80–90 USD per dose in the US commercial market
- Availability: Widely available at US retail pharmacies, clinics, and health systems
- Target audience: Adults and children six months and older following CDC COVID-19 booster guidance
- Standout / USP: First fully approved mRNA COVID-19 vaccine in the US, with extensive real-world data across billions of administered doses
This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.
